Blueprint Genetics’ highlights at ACMG 2018

Published on April 26, 2018

Image for Blueprint Genetics’ highlights at ACMG 2018

What are the most inspiring takeaways from the scientific sessions? How does NGS genetic testing provide clinicians a better tool to diagnose patients? In this podcast, Genetic Services Consultant Adam Beres and Clinical Interpretation Team Leader Eveliina Salminen discuss the highlights of the 2018 Annual Clinical Genetics Meeting (2018) organized in Charlotte, NC, USA.

Eveliina addresses the most interesting topics from the scientific sessions, e.g. how NGS genetic testing has provided clinicians with a powerful tool to better diagnose patients. In addition, we hear greetings from the lively exhibition floor and what are the latest developments at Blueprint Genetics, including the recent panel update and technological improvements.

Episode guests

Eveliina Salminen

Eveliina Salminen

Eveliina is the Head of Clinical interpretation and Clinical geneticist at Blueprint Genetics. She obtained her Ph.D on genetics of multiple epiphyseal dysplasia and osteoarthritis in 2005 followed by post-doctoral studies concentrated on genetics of multiple sclerosis, population genetics and Mendelian disease-gene mapping at the Broad Institute, MA, USA and National Public Health Institute, Helsinki, Finland. Eveliina has also worked as a geneticist in Finnish Genome Center in Helsinki with genome-wide and custom SNP chip projects doing project planning, management, genotyping and data analysis. She has Specialist training in Clinical genetics: both clinical (Dept of Clinical Genetics and Prenatal diagnostic unit, Helsinki University Central Hospital) and laboratory experience (HUSLAB, Laboratory of genetics).

Adam Beres

Adam Beres

Adam is Genetic Services Consultant at Blueprint Genetics based in Ohio River Basin territory. Adam joined Blueprint Genetics in August 2017. He has over a decade of experience from pharma and molecular diagnostics industries.

Last modified: 04.30.2018

What do you want to hear next?